key: cord-0710220-30er0d38
authors: Nassabein, Rami; Routy, Bertrand; Blais, Normand; Ayoub, Jean-pierre; Tehfé, Mustapha
title: Arterial Thrombosis and Covid-19 in a Cancer patient
date: 2020-05-18
journal: Eur J Cancer
DOI: 10.1016/j.ejca.2020.05.002
sha: ae3637f1a5494a7426cfca0c72be9a3c868ce3fe
doc_id: 710220
cord_uid: 30er0d38

nan

Preliminary reports have pointed out to an increased risk of thrombotic events in patients diagnosed with coronavirus disease 2019 (Covid-19) (1, 2) and optimal prophylactic strategies remain unknow. Herein, we report the case of a cancer patient, positive for Covid-19 who developed an extensive intraaortic thrombosis.

A 66-year old female known for hypertension, osteopenia, anxiety and a benign thyroid nodule was diagnosed 4 months ago with a non-operable intrahepatic cholangiocarcinoma. She had no prior thrombosis. Patient was started on chemotherapy with cisplatin and gemcitabine. Day eight of her second cycle, she reported 24 hr of fever associated with dry cough, nasal congestion and dyspnea on exertion. Patient was admitted to the hospital and tested positive for SARS-CoV-2 PCR nasal swab. On admission, blood results showed a normal complete blood count beside a mild lymphopenia (0.7 x10 9 /Liter), and normal INR and PTT but elevated Fibrinogen (6.3 g/L) and an elevated D-dimer level (1588 microgram/liter). Chest X-ray revealed wedge infiltrates in the left superior lobe. She was started on ceftriaxone and azithromycin, oxygen support and prophylactic low-molecular-weight-heparin (LMWH).

On day 3 of her hospitalization, patient remained febrile and complained of a new right upper quadrant abdominal pain. Antibiotics were changed for piperacillin-tazobactam and vancomycin and a CT angioscan of the chest and abdomen-pelvic scan were performed. Findings were consistent with covid-19 infection, with bilateral ground-glass infiltrates in the chest. There was no pulmonary embolism nor progression of her cholangiocarcinoma. However, arterial series revealed multiple thrombi in the descending thoracic aorta and in the abdominal aorta near celiac trunk (figure-1). She had no sign or symptoms of cerebrovascular or other peripheral arterial occlusion. All blood cultures were negative. Aspirin was started and LMWH was changed to therapeutic dose. Subsequent serological testing was negative for antiphospholipid antibodies.

Arterial thromboembolic events in cancer patients on cisplatin-based chemotherapy are known complication reported in <1%(3), but extensive aortic thrombi are rare(4). This report of arterial thrombosis despite optimal prophylactic treatment highlights the prothrombic risk associated with Covid-19 infection, potentially compounded by cisplatin use and a para-neoplastic prothrombotic state. Reports suggest that inflammatory cytokines released during Covid-19 infection are associated with endothelial vascular damage which may favour disseminated thrombosis (5) . Important questions raised by this case and others concern the adequacy of standard prophylactic doses of LMWH in Covid-19 disease. In a broader view, perhaps that wider use of anticoagulants in adult ambulatory patients undergoing chemotherapy, as recently shown by Khorana et al.(6) should be emphasized in the setting of the Covid-19 pandemic. Studies are currently evaluating different strategies to increase the doses of thromboprophylaxis LMWH in patients with covid-19 and elevated baseline pro-thrombotic risk factors such as cancer.

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. 2020:e38

ST-Segment Elevation in Patients with Covid-19 -A Case Series

Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! Thrombosis journal

Acute aortic thrombosis in patients receiving cisplatin-based chemotherapy

COVID-19 and its implications for thrombosis and anticoagulation

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer

Figure-1: Scan of the thorax and abdomen showing the aortic thrombi at different levels as filling defects pointed by arrows

None of the authors has any conflict of interest to disclose related to the case.